Cyclosporine A improves ulcerative colitis complicated with deep vein thrombosis with coagulation abnormalities
1 Department of Bacteriology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
2 Department of Gastroenterology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Case Study
World Journal of Advanced Research and Reviews, 2023, 20(01), 1017–1021
Article DOI: 10.30574/wjarr.2023.20.1.2150
Publication history:
Received on 12 September 2023; revised on 23 October 2023; accepted on 25 October 2023
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum. UC patients are at increased risk of deep vein thrombosis. Cyclosporine A (CyA) is an immunosuppressant drug that is used to treat severe UC. A 49-year-old man with UC complicated by DVT was treated with CyA. The patient presented with severe bloody diarrhea, lower extremity edema, and a clinical activity index of 16. The patient's coagulation test results were also abnormal. After CyA administration, the patient's leg pain and swelling improved. In addition, the extrinsic coagulation abnormalities improved first after CyA administration, followed by a gradual improvement in the intrinsic coagulation abnormalities. CyA may be effective in correcting coagulation abnormalities that contribute to DVT in UC patients.
Keywords:
Cyclosporine A; Ulcerative Colitis; Venous Thrombosis; Coagulation Disorder
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0